LEXUS CULINARY MASTERS WELCOMES SHOTA NAKAJIMA
Chef brings passion for Japanese flavors and hospitality to distinguished culinary roster
Trained under Michelin Star-rated Chef
Combining the formidable experience with his own perspective and imaginative applications, his dream was realized at age 25 with the opening of his restaurant,
"Serving up modern dishes that masterfully encapsulate the traditional flavors of our Japanese heritage,
"I'm honored to be recognized alongside a celebrated team of culinary visionaries," said
As a Lexus Culinary Master, Nakajima will partner with the brand on marketing initiatives and food and wine events. In
The Lexus Culinary Masters team is currently comprised of some of the country's most prestigious chefs, restaurateurs and culinary personalities. Nakajima joins
About Lexus
Lexus' passion for brave design, imaginative technology, and exhilarating performance enables the luxury lifestyle brand to create amazing experiences for its customers. Lexus began its journey in 1989 with two luxury sedans and a commitment to pursue perfection. Since then, Lexus has developed its lineup to meet the needs of global luxury customers in more than 90 countries. In
www.facebook.com/lexus
www.twitter.com/lexus
www.youtube.com/LexusVehicles
www.instagram.com/lexususa
https://www.pinterest.com/lexususa
Note to Editors: Lexus product information and images are available online via our news media website http://LexusNewsroom.com.
MEDIA CONTACTS:
469-980-1017
[email protected]
310-437-2500
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/lexus-culinary-masters-welcomes-shota-nakajima-302036034.html
SOURCE Lexus
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- Surplus Solutions, an NMS Capital Portfolio Company, Accelerates Technical Service Capabilities; Announces Partnership with DCM BioServices
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Sanford C. Bernstein, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share